Share 'Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy by Year End 2014'
Great investor call from Sarepta this morning on the heels of the news about positive signals from the FDA for submitting a new drug application! We are speaking with the company this morning and will release a detailed statement this afternoon. Congratulations to everyone!
Sarepta's Press Release:
-- FDA provides updated guidance on potential early approval pathway for eteplirsen;
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this